A. Goerlitz

A randomized, double‐blind, phase 2 study of erythropoietin in optic neuritis

B. Seitz, W. Reith, M. Bähr, 2012, Annals of neurology.

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.

N. Schmitz, M. Pfreundschuh, P. Dreger, 2014, The Lancet. Oncology.

Natriuretic Peptides for the Detection of Paroxysmal Atrial Fibrillation in Patients with Cerebral Ischemia – the Find-AF Study

R. Wachter, G. Hasenfuss, F. Edelmann, 2012, PloS one.

Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.

N. Schmitz, P. Dreger, G. Wulf, 2008 .

Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients

Tim Friede, Raees Ahmed, Oliver Gross, 2012, ISRN pediatrics.